Peculiarities of neuroprotective therapy in women with acute ischemic stroke
DOI:
https://doi.org/10.14739/2310-1210.2020.4.208352Keywords:
stroke, women, neuroprotection, edaravoneAbstract
There are significant differences between the course of acute ischemic stroke (AIS) in men and women. On average, women with AIS have a more pronounced degree of neurological disorders, higher mortality and disability. However, carotid procedures and thrombolytic therapy are performed less frequently in women than in men, requiring the search for alternative therapies for the treatment of AIS in women (neuroprotection).
Aim. To investigate the effectiveness of a combination therapy with edaravone as a neuroprotector in women with AIS.
Materials and methods. A prospective study enrolled 48 women with AIS, divided into two groups. The first group patients (n = 36) were treated with edaravone 30 mg twice daily, intravenously. Neuroprotectors were not used in the control group (n = 12). Clinical-instrumental and neurological examinations (Glasgow Coma Scale (GCS), FOUR, NIHSS, neurospecific enolase (NSE) levels) were performed in all the patients.
Results. An analysis of GCS scores showed a positive trend in most patients of both groups, with no difference between the groups. Thus, the mean GCS score in the main group increased from 11.84 ± 2.62 to 13.87 ± 0.94 points against 11.69 ± 3.15 to 13.31 ±1.78 in the control group (P > 0.05). The FOUR score showed that in group 1, the level of consciousness recovered more rapidly from the 5th day and up to 9–10 days of treatment it was: in the edaravone group – 15.47 ± 0.85 points, in the control group – 13.62 ± 1.19 points (P < 0.05). The level of NSE was higher than normal in all the women, with the highest level in patients of the control group, in whom it increased 10-fold (from 9.2 to 96.4 ng/ml, P < 0.01). Later on, there was a rapid decrease in NSE level in group 1, while the level of NSE did not reach the reference values (P < 0.05) until day 10 of treatment in the control group.
Conclusions. The administration of edaravone in women with AIS resulted in favorable outcomes even in the acute period of the disease. The use of edaravone was significantly effective on the FOUR scale and by the dynamics of NSE levels. Further studies are needed to clarify the role and place of edaravone in the ischemic stroke intensive care setting.
References
Tomaszewski, M., Topyła, W., Kijewski, B. G., Miotła, P., & Waciński, P. (2019). Does gender influence the outcome of ischemic heart disease? Menopausal Review, 18(1), 51-56. https://doi.org/10.5114/pm.2019.84158
Christensen, H., Bentsen, L., & Christensen, L. (2016). Update on specificities of stroke in women. Presse medicale (Paris, France: 1983), 45(12 Pt. 2), e409-e418. https://doi.org/10.1016/j.lpm.2016.10.005
Di Carlo, A., Lamassa, M., Baldereschi, M., Pracucci, G., Basile, A. M., Wolfe, C. D., Giroud, M., Rudd, A., Ghetti, A., Inzitari, D., & European BIOMED Study of Stroke Care Group. (2003). Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke, 34(5), 1114-1119. https://doi.org/10.1161/01.STR.0000068410.07397.D7
Girijala, R. L., Sohrabji, F., & Bush, R. L. (2017). Sex differences in stroke: Review of current knowledge and evidence. Vascular medicine, 22(2), 135-145. https://doi.org/10.1177/1358863X16668263
Lundberg, G. P., & Volgman, A. S. (2016). Burden of stroke in women. Trends in Cardiovascular Medicine, 26(1), 81-88. https://doi.org/10.1016/j.tcm.2015.04.010
Triches, C., Schaan, B. D., Gross, J. L., & Azevedo, M. J. (2009). Macrovascular diabetic complications: clinical characteristics, diagnosis and management. Arquivos brasileiros de endocrinologia e metabologia, 53(6), 698-708. https://doi.org/10.1590/s0004-27302009000600002
Appelros, P., Stegmayr, B., & Terént, A. (2009). Sex Differences in Stroke Epidemiology. Stroke, 40(4), 1082-1090. https://doi.org/10.1161/strokeaha.108.540781
Jerath, N. U., Reddy, C., Freeman, W. D., Jerath, A. U., & Brown, R. D. (2011). Gender Differences in Presenting Signs and Symptoms of Acute Ischemic Stroke: A Population-Based Study. Gender Medicine, 8(5), 312-319. https://doi.org/10.1016/j.genm.2011.08.001
Labiche, L. A., Chan, W., Saldin, K. R., & Morgenstern, L. B. (2002). Sex and acute stroke presentation. Annals of emergency medicine, 40(5), 453-460. https://doi.org/10.1067/mem.2002.128682
Alamowitch, S., Eliasziw, M., Barnett, H. J., North American Symptomatic Carotid Endarterectomy Trial (NASCET), ASA Trial Group, & Carotid Endarterectomy (ACE) Trial Group. (2005). The risk and benefit of endarterectomy in women with symptomatic internal carotid artery disease. Stroke, 36(1), 27-31. https://doi.org/10.1161/01.STR.0000149622.12636.1f
Moretti, A., Ferrari, F., & Villa, R. F. (2015). Neuroprotection for ischaemic stroke: current status and challenges. Pharmacology & therapeutics, 146, 23-34. https://doi.org/10.1016/j.pharmthera.2014.09.003
Watanabe, K., Tanaka, M., Yuki, S., Hirai, M., & Yamamoto, Y. (2018). How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? Journal of clinical biochemistry and nutrition, 62(1), 20-38. https://doi.org/10.3164/jcbn.17-62
Kern, R., Nagayama, M., Toyoda, K., Steiner, T., Hennerici, M. G., & Shinohara, Y. (2013). Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovascular diseases, 35(5), 402-418. https://doi.org/10.1159/000351753
Kaste, M., Murayama, S., Ford, G. A., Dippel, D. W., Walters, M. R., Tatlisumak, T., & MCI-186 study group. (2013). Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovascular diseases, 36(3), 196-204. https://doi.org/10.1159/000353680
Yamaguchi, T., Awano, H., Matsuda, H., Tanahashi, N., & PROTECT4.5 Investigators. (2017). Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). Journal of stroke and cerebrovascular diseases, 26(4), 756-765. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.10.011
Yang, J., Cui, X., Li, J., Zhang, C., Zhang, J., & Liu, M. (2015). Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. Developmental neurorehabilitation, 18(5), 330-335. https://doi.org/10.3109/17518423.2013.830153
Edaravone Acute Infarction Study Group. (2003). Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovascular diseases, 15(3), 222-229. https://doi.org/10.1159/000069318
Kimura, K., Aoki, J., Sakamoto, Y., Kobayashi, K., Sakai, K., Inoue, T., Iguchi, Y., & Shibazaki, K. (2012). Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients - A preliminary study. Journal of the neurological sciences, 313(1-2), 132–136. https://doi.org/10.1016/j.jns.2011.09.006
Manwani, B., & McCullough, L. D. (2019). On the Basis of Sex. Stroke, 50(9), 2285-2287. https://doi.org/10.1161/STROKEAHA.119.025955
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
